Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1822924
Max Phase: Preclinical
Molecular Formula: C43H65N5O9
Molecular Weight: 796.02
Molecule Type: Small molecule
Associated Items:
ID: ALA1822924
Max Phase: Preclinical
Molecular Formula: C43H65N5O9
Molecular Weight: 796.02
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C/C=C\[C@H](C)[C@H](OC(=O)NCCCNC(=O)c1cccc(N=[N+]=[N-])c1)[C@@H](C)[C@H](O)[C@@H](C)C/C(C)=C\[C@H](C)[C@@H](O)[C@@H](C)/C=C\[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C
Standard InChI: InChI=1S/C43H65N5O9/c1-10-11-14-27(4)40(57-43(55)46-20-13-19-45-41(53)33-15-12-16-34(23-33)47-48-44)31(8)38(51)29(6)22-25(2)21-28(5)37(50)26(3)17-18-35(49)24-36-30(7)39(52)32(9)42(54)56-36/h10-12,14-18,21,23,26-32,35-40,49-52H,1,13,19-20,22,24H2,2-9H3,(H,45,53)(H,46,55)/b14-11-,18-17-,25-21-/t26-,27-,28-,29-,30-,31-,32+,35+,36-,37-,38+,39-,40-/m0/s1
Standard InChI Key: XHLXKZHSJZBMGZ-FVXUXLCOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 796.02 | Molecular Weight (Monoisotopic): 795.4782 | AlogP: 6.69 | #Rotatable Bonds: 22 |
Polar Surface Area: 223.41 | Molecular Species: ACID | HBA: 10 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: -10.52 | CX Basic pKa: | CX LogP: 5.75 | CX LogD: 5.64 |
Aromatic Rings: 1 | Heavy Atoms: 57 | QED Weighted: 0.01 | Np Likeness Score: 1.54 |
1. Smith AB, Sugasawa K, Atasoylu O, Yang CP, Horwitz SB.. (2011) Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity., 54 (18): [PMID:21870795] [10.1021/jm200692n] |
2. Nadaradjane C, Yang CH, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, Smith AB, Horwitz SB, McDaid HM.. (2018) Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners., 81 (3): [PMID:29522336] [10.1021/acs.jnatprod.8b00111] |
Source(1):